We compared UCB mononuclear cells (MNC) with CD34
however, cord blood transplantation can now be considered as an established progenitor cell source for transplantation in malignant as well as non-malignant disease. 7 To expand the recipient population, ex vivo expansion of UCB derived hematopoietic progenitor cells is of special interest in the adult transplantation setting. Ex vivo expanded cord blood cells have successfully engrafted myeloablated animals. [8] [9] [10] Also, ex vivo expanded cells have been used in human autologous transplantation to reduce tumor cell contamination of the graft and accelerate engraftment. 11 In allogeneic transplantation experience with ex vivo expanded grafts is very limited. For in vitro studies, most groups perform CD34 + cell selection before initiating cell culture, since this leads to increased and more reliable expansion. 12 But CD34
+ cell selection itself is associated with a substantial loss of progenitor cells. 13 Furthermore, as UCB is cryopreserved in cord blood banks as whole blood or as the mononuclear cell fraction (MNC), CD34
+ selection would have to be done with thawed material, which is associated with increased cell losses as compared to unfrozen material. 14, 15 In this study we compared the proliferation characteristics of mononuclear UCB with CD34
+ selected UCB cells and tried to define the importance of T cells for CD34 + cell expansion in the MNC fraction. We also looked at the role of refeeding and reseeding of cultures. Conventional cytogenetic analysis was performed to assess genetic stability of ex vivo expanded human UCB.
Materials and methods

Collection of maternal and umbilical cord blood samples
Cord blood was collected immediately after delivery by the obstetric service as follows: the umbilical cord was doubly clamped, transected 7-10 cm away from the umbilicus, the exterior of the cord cleaned with 70% ethanol and the umbilical vein punctured with a 50 ml syringe containing 2 ml of heparin (Liquemin; Roche, Grenzach, Germany). Informed consent was obtained according to institutional guidelines.
Cell preparation and cell cultures
Mononuclear cells (MNC) were isolated from maternal and cord blood on a density gradient (Lymphoprep, density 1.077 g/ml; Nycomed, Oslo, Norway) according to standard procedures. Cultures were started in 24-well plates (Nunc, Naperville, IL, USA). The unseparated MNC fraction was seeded at a concentration of 1 × 10 6 cells/ml in 1 ml Iscove's modified Dulbeccos's medium (IMDM; Gibco, Paisley, UK) containing 130 ng/ml SCF (Amgen, Munich, Germany), 8 ng/ml IL-3 (Behring, Marburg, Germany), 20 ng/ml IL-6 (Genetics Institute, Cambridge, MA, USA), 13 ng/ml G-CSF (Amgen), 0.4 U EPO (Cilag, Schaffhausen, Switzerland) and 50 ng/ml flt-3L (ICC, Ismaning, Germany) (referred to as culture medium). Unless otherwise noted, no reseeding or refeeding of either cytokines or medium was performed during the culture period. Different wells were harvested on days 0, 7 and 14 for analysis. CD34 + cell selection was performed with the Miltenyi MiniMACS column according to the manufacturer's manual. Briefly, umbilical cord blood MNC were incubated for 15 min at 4°C with human IgG to block the Fc receptor and an anti-CD34 antibody (QBEND10; Miltenyi Biotec, Bergisch-Gladbach, Germany) modified with a hapten. Cells were washed with degassed PBS with HSA 0.5% (DRK, Springe, Germany) and ACD-A 0.5% (Ivex Pharmaceuticals, Larne, UK) (referred to as MiniMACS buffer) and incubated for 15 min with an anti-hapten mouse monoclonal antibody conjugated to colloidal superparamagnetic beads (Miltenyi Biotech). Labeled cells were applied to magnetic columns (MS columns, Miltenyi Biotec), unbound cells washed out and positive cells eluted from the column outside the magnet with 1 ml MiniMACS buffer. The CD34 + selected fraction was seeded in 24-well plates at a concentration of 2 × 10 5 cells/ml in 1 ml of culture medium. On days 0, 7 and 14, cells were collected from the wells and analyzed.
For reseeding and refeeding experiments with the MNC as well as the CD34 + selected fraction, cultures from one cord blood collection were initiated in at least two different wells. Cells from one well were harvested on day 7, counted, washed and resuspended in new culture medium at the same concentration as on day 0. On day 14 these cells were compared to control wells which were left untouched after initiation of culture.
T cell depletion
CD3
+ depletion was performed with the Miltenyi Mini-MACS column. Briefly, umbilical cord blood MNC were incubated for 15 min at 4°C with human IgG to block the Fc receptor and a FITC-conjugated anti-CD3 antibody (OKT-3; Ortho Diagnostic System, Raritan, NJ, USA). Cells were washed with MiniMACS buffer and incubated for 15 min with anti-FITC micro beads (Miltenyi Biotech). Labeled cells were applied to magnetic columns (MS columns, Miltenyi Biotec) and unbound cells were washed out. The CD3
+ depleted fraction was seeded in 24-well plates at a cell concentration of 1 × 10 6 cells/ml in 1 ml of culture medium. On days 0, 7 and 14, cells were collected from the wells and analyzed.
For functional T cell abrogation 30 l OKT-3/ml was added to MNC on day 0. Wells and control wells were harvested and counted on day 7, colony assays and flow cytometric analysis performed on days 0 and 7.
CFU progenitor assay
CFU progenitor assays were performed with phytohemaglutinin-stimulated leukocyte-conditioned media (PHA-LCM) in a premixed medium (Terry Fox Laboratory, Vancouver, Canada) at a final concentration of 0.8% methylcellulose, 30% heat-inactivated FCS, 1% bovine serum albumin, 10 −4 m 2-mercaptoethanol, 3 units/ml EPO, and 10% agar-LCM with 5% serum-containing PHA-LCM. Each assay was plated as triplicate with 10 4 cells/ml/Petri dish (MNC) or 10 3 cells/ml/Petri dish (CD34 selected fraction) at 37°C in a humidified atmosphere of 5% CO 2 in air. After 14 days of incubation, clusters (20-50 cells) and colonies (Ͼ50 cells, scored as pluripotent colonies (CFU-GEMM), white cell precursors (CFU-GM), early (BFU-E) and more differentiated (CFU-E) red cell precursors) were counted.
Flow cytometry
For FACS analysis 5 × 10 5 cells (1 × 10 5 of the CD34 + selected fraction) were washed in PBS containing 0.5% BSA and 0.01% NaN 3 . Twenty microliters human immunoglobulin solution (Gammagard, Baxter, Germany) and 20 l rabbit serum (Gibco, Paisley, UK) were added to block non-specific binding. For CD34 + cell measurement 20 l of a PE-conjugated anti-CD34 antibody (HPCA-2; Becton Dickinson, Heidelberg, Germany) and 1.2 l of a FITC-conjugated lineage-associated marker (CD64, clone 32.2; Medarex, Annandale, NJ, USA) were added. Anti-CD3 and anti-CD33 antibodies were FITC conjugated, the anti-CD19 antibody was PE conjugated (Coulter Immunotech, Krefeld, Germany). Twenty microliters of antibody were added, followed by 30 min incubation time. After washing, cells were incubated with 100 l of freshly reconstituted propidium iodide (PI; Sigma, Deisenhofen, Germany) at 2 g/ml for 10 min, washed and diluted in 0.5 ml buffer for analysis. All incubation and washing steps were done on ice and protected from light. To enumerate CD34 + cells, debris and PI positive (ie dead) cells were excluded. CD34-PE bright to intermediate CD64-FITCnegative cells with low side scatter properties were gated and counted. All events were backgate controlled.
Analysis was done on a FACScan (Becton Dickinson, Heidelberg, Germany) with CellQuest software.
Conventional cytogenetic analysis
Classical cytogenetic analysis was performed using standard procedures after 14-16 h incubation with 0.01 g/ml colcemid (Life Technologies, Eggenstein, Germany). Chromosomes were identified using a modified G-banding technique, and classified according to 'An International System for Human Cytogenetic Nomenclature' (ISCN).
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Results
Cell number
The mononuclear cell fraction was seeded at a concentration of 1 × 10 6 cells/ml on day 0, since a lower starting cell dose did not lead to reliable cell proliferation. Without refeeding and reseeding we could see a 1.6-fold increase in overall cell numbers on day 7 and 2.3-fold on day 14 ( Table 1) .
Cultures of the positive fraction with a mean purity of 62.6% CD34 + cells were initiated at a concentration of 2 × 10 5 cells/ml. Without refeeding or reseeding the increase in overall cell numbers was 7-fold on day 7 and 12.2-fold on day 14 ( Table 1) . A reduced starting cell dose did not improve cell expansion significantly.
CD34
+ cell expansion and cell differentiation
The CD34 + cell expansion in the MNC fraction is summarized in Table 1 . The CD3 + T cell content declined during culture from a mean of 13% (s.e.m. Ϯ 8.3%) on day 0 to 8.1% (s.e.m. Ϯ 7.7%) on day 7 and 6% (s.e.m. Ϯ 7%) on day 14 (n = 6, data not shown). Likewise, CD19
+ B cells decreased from 5.7% (s.e.m. Ϯ 1.7%) on day 0 to 1.8% (s.e.m. Ϯ 1.3%) on day 7 and 1% (s.e.m. Ϯ 0.8%) on day 14 (n = 6, data not shown). CD33
+ cell content increased during culture from a mean of 8.9% (s.e.m. Ϯ 3.5%) on day 0 to 39.8% (s.e.m. Ϯ 14.9%) on day 7 and 42.6% (s.e.m. Ϯ 18.5%) on day 14 (n = 6, data not shown).
The CD34 + enriched cell fraction was seeded at a mean CD34 + cell concentration of 62.6%; culture characteristics are summarized in Table 1 . The percentage of CD33 + cells increased from day 0 with a mean of 38.6% (s.e.m. Ϯ 13.9%) to 82.1% (s.e.m. Ϯ 1.9%) on day 7 and declined towards 40.8% (s.e.m. Ϯ 4.5%) on day 14 (n = 4, data not shown). CD19 + B cells decreased from 7.4% (s.e.m. Ϯ 2.4%) on day 0 to 0.5% on days 7 and 14 (s.e.m. Ϯ 0.2% and Ϯ0.4%, respectively) (n = 4, data not shown).
Peroxidase staining revealed emerging positivity in the mononuclear as well as CD34
+ selected cell fraction indicating myeloid differentiation in both settings ( Table 2) . The ␣-naphthylacetatesterase staining for monocytoid/ macrophage differentiation, however, revealed clearly brighter esterase positive macrophages after culture of Percentage of dead cells was determined by propidium iodide staining and flow cytometry. CD34 + selected cells show a significantly better cell number expansion than mononuclear cells (P = 0.018). The mononuclear cell fraction, however, can increase the percentage and overall number of CD34 + cells during culture as opposed to the CD34 + selected cells. The overall increase in CD34 + cells is significant for the mononuclear cell fraction with P = 0.0015 comparing day 7 to day 0, but not significant comparing day 14 to day 0 because of the elevated standard deviation (P = 0.0712, Wilcoxon signed rank test).
MNCs as compared to CD34
+ selected cells (Table 2 , Figure 1 ).
Colony assay
Plating 10
4 MNC/ml on day 0 a median of 27.1 (s.e.m. Ϯ 15.2) total colonies (including clusters, CFU-GM, BFUe, CFUe and CFU-GEMM) and 9.9 (Ϯ2.3) CFU-GM could be enumerated. On day 7 we saw a six-fold increase (s.e.m. Ϯ 4) in total colonies per 10 4 seeded cells, the increase in CFU-GM was 11.1-fold (s.e.m. Ϯ 8). On day 14 the increase in total colonies per seed declined to 2.5-fold (s.e.m. Ϯ 1.6), the increase in CFU-GM was 4.1-fold (s.e.m. Ϯ 2.7) as compared to day 0. The number of BFU-E and CFU-GEMM rapidly declined during the culture period. Taking cell number proliferation into consideration, the absolute increase in colonies was 9.2-fold (s.e.m. Seeding 10 3 CD34 enriched cells/ml on day 0 a median of 70.5 (s.e.m. Ϯ 25.5) total colonies and 31.7 (Ϯ8.7) CFU-GM could be enumerated. The CD34 + selected cell fraction showed a 7.6-fold (s.e.m. Ϯ 4.1) and 6.4-fold (s.e.m. Ϯ 4.6) increase in total colonies on days 7 and 14, and a 11.3-fold (s.e.m. Ϯ 6.9) and 9.9 (s.e.m. Ϯ 6.8)-fold increase in CFU-GM on days 7 and 14, respectively. In contrast to the MNC fraction, this increase in colonies is mainly due to cell number proliferation and not because of an increase in cloning efficiency, since the number of colonies per 10 3 cells declined to 63.5 (s.e.m. Ϯ 12.4) on day 7 and 37.5 (s.e.m. Ϯ 14.7) on day 14. As in the MNC fraction the number of BFUe and GEMM rapidly declined during the culture period (data not shown).
Refeeding and reseeding
The MNC fraction did not profit from refeeding and reseeding: cell numbers decreased after refeeding and reseeding as did the percentage of CD34 + cells (data not shown). For the CD34 + selected fraction, however, refeeding and reseeding on day 7 resulted in an increase from 16.3-fold cell number proliferation to 58.1-fold, demonstrated in Table 3 and Figure 3 . This improved cell number prolifer- + selected cells as revealed by the increased positivity for ␣-naphthylacetatesterase staining. POX = peroxidase staining; Esterase = ␣-naphthylacetatesterase staining; ND = not done; Staining intensity: + dim, ++ medium, +++ bright. ation was paralleled by a decreased percentage of CD34 + cells thus indicating that differentiation occurred (Table 3) .
T cell depletion
One of the major differences between the mononuclear vs CD34 + selected cell fraction was the increase in the percentage of CD34
+ cells observed only with the MNC fraction during culture. Accessory cells present in the MNC but not in the CD34 + selected fraction could directly (via cell-cell interaction) or indirectly (via cytokine production) be responsible for this effect. Since T cells are potent producers of several important cytokines, we looked at the effect of T cell depletion on the growth characteristics of the MNC fraction. We could achieve a mean 1.2-fold T cell depletion (s.e.m. Ϯ 0.85), meaning that after depletion still 2.69% (s.e.m. Ϯ 2.5) T cells were present. The immunomagnetic separation itself did not alter growth characteristics significantly (data not shown). Table 4 summarizes our results: T cell depletion leads to an increased number of dead cells and a markedly decreased CD34 + cell expansion as compared to the unmanipulated MNC.
The total number of colony-forming units for the depleted samples was 1.7 (s.e.m. Ϯ 0.9)-fold higher than for the unmanipulated controls on day 0 with a cloning efficiency of 0.33 vs 0.21%, respectively. On day 7, how- + selected cells. 'per seed' gives the fold increase in CFU-GM without correcting for cell number proliferation thus indicating clonogenicity of a given cell number. 'overall' takes into account cell number proliferation during culture period thus representing the absolute increase in colonies. Cord blood MNC show an increase in clonogenicity during culture, which cannot be observed for CD34 + selected cells. The increased proliferative potential of the CD34 + selected fraction (see Table 1 ) compensates for this decrease in clonogenicity, so that overall increase in CFU-GM over time seems to be comparable for cord blood MNC vs CD34 + selected cells with a slight advantage for MNC on day 7. ever, the controls showed a 5.9 (s.e.m. Ϯ 1.7)-fold and on day 14 a 2.5 (s.e.m. Ϯ 1.5)-fold increase in total colonies, whereas the T cell-depleted samples achieved only a 2.9 (s.e.m. Ϯ 1.2)-fold and 0.9 (s.e.m. Ϯ 0.5)-fold increase on days 7 and 14, respectively (data not shown). To verify these results functional abrogation of T cells by the addition of OKT-3 antibody to cultures was performed in another set of experiments. The % living cells on day 7 declined from 94.6% (s.e.m. Ϯ 0.5) without to 51% (s.e.m. Ϯ 5.3) with T cell blockage accompanied by a significant decrease in colony formation (n = 5, data not shown). Static cultures were initiated in at least two different wells as described in Materials and methods. On day 7, cultures in one well were continued without manipulation, cells from the other well were reseeded at the initial concentration in new medium. On day 14 wells were harvested and overall cell numbers determined (n = 4). 
Genetic stability
Nine MNC samples were investigated including three samples on day 0 and six samples after a period of more than 7 days of culture. All 36 metaphases of the cord blood MNC examined on day 0 revealed normal karyotypes. Sporadic chromosomal aberrations were found in 4% of 100 metaphases of six samples examined after ex vivo expansion including one numerical and three structural chromosome changes. However, these chromosome abnormalities occurred in one cord blood (CB013) sample, only.
Discussion
Allogeneic progenitor cell transplantation is the preferred treatment for a variety of diseases ranging from inborn errors of metabolism to leukemia. 18 The main limiting factor for an increased use of UCB transplantation in adults seems to be the small number of progenitor cells available. 5 Therefore, much effort has focused on the in vitro expansion of cord blood cells. [19] [20] [21] [22] [23] However, the optimal culture conditions for clinical use have not been defined as yet. For successful clinical use of ex vivo expanded material several prerequisites need to be fulfilled: to minimize the risk of contamination, extensive manipulation during the culture period should be avoided. Cultures should be stroma free to prevent any carryover of an HLA mismatched or even xenogeneic feeder layer into an immunocompromised host. Also, because of the risk of transmission of infections, fetal calf serum should not be used. Results have to be reproducible and the expanded cells need to have appropriate functional activity and genetic stability.
Most experience with the expansion of hematopoietic progenitor cells has been obtained with CD34
+ selected cell fractions to achieve better cell number proliferation during culture. 12 However, cord blood samples collected and stored in cord blood banks so far are either whole blood, erythrocyte-depleted or mononuclear cells. 24 CD34 + selection itself leads to a loss of CD34
+ cells in the range of 50%.
13 CD34 + selection of a thawed potential graft is more difficult to perform and probably associated with even increased cell losses, 14, 15 although this opinion is not shared by all groups. 25 Also, CD34 + selection is expensive, timeconsuming and associated with extensive manipulation. The mononuclear cell fraction of human umbilical cord blood may therefore represent the better starting cell population.
We compared UCB mononuclear cells with CD34 + selected cells on a static culture system on a preclinical scale without fetal calf serum or a feeder layer. Neither refeeding of culture medium or cytokines nor reseeding of cells was performed in the initial experiments to minimize any manipulation. As indicated in Table 1 the cell number proliferation for cord blood MNC in static cultures is clearly inferior to CD34 + selected samples. When focusing on the expansion of CD34 + cells as markers for early hematopoietic progenitors, cord blood MNC show a substantial increase from 0.94% CD34 + cells on day 0 to 5.8% on day 7 (Table 1) . Therefore, the limited cell number proliferation is in part compensated by a selective proliferation of the CD34 + compartment. In the CD34 + selected samples, on the other hand, the percentage of CD34
+ cells declined continously with culture period (Table 1) .
In our culture system with early and late acting cytokines we observed cell differentiation of the progenitor cell pool. This indicates that the increase in CD34
+ cells is not so much because of an expansion of the early but rather late progenitor pool. This interpretation is supported by the observed increase in total colonies which represent the committed hematopoietic progenitor pool (Figure 2 ). In addition, we observed emerging peroxidase positivity as a marker for myeloid differentiation in both MNC and CD34 + selected samples, whereas the MNC fraction revealed more ␣-naphthylacetatesterase positive macrophages when compared to the CD34 + -selected group (Table 2 ). This could be due to additional factors secreted by the numerous accessory cells present in the MNC but not so much in the CD34 + selected samples. In a clinical setting this may lead to altered graft-versus-host or graft-versus-leukemia properties (which are both in part mediated by monocytes/ macrophages).
Analyzing colony assays as functional markers for progenitor cell activity, we saw a differentiation towards CFU-GM with a decreasing BFU-E content in both the MNC as well as CD34 + selected cells. This is probably due to our cytokine cocktail which -although containing erythropoietin -did not support proliferation of red cell precursors. The number of CFU-GM clearly increased during culture of both the mononuclear as well as CD34 + selected cells. Refeeding and reseeding of CD34 enriched cells leads to an improved cell number proliferation mainly because of a more rapid differentiation of hematopoietic progenitor cells, as the decreasing percentage of CD34 + cells shows (Table 3) . Another problem of reseeding is the extensive manipulation increasing the risk of contamination. Here the development of continuous perfusion cultures or bioreactors might help to secure the medium exchange and reseed effect while allowing growth of cells within the same flask/reactor during culture period. Recent data have already revealed the possibility of successful expansion of mononuclear cells from bone marrow or peripheral blood in bioreactors without a feeder layer. 26, 27 First results with umbilical cord blood mononuclear cell expansion in an automated perfusion culture system have been published very recently proving the extensive potential of cord blood mononuclear cells especially for CFU-GM expansion. 28, 29 The most interesting point in culturing umbilical cord blood mononuclear cells is the observed increase in CD34 + cells proportionally as well as in absolute numbers while the overall cell number proliferation is only very moderate (Table 1 ). This effect could not be observed if cord blood samples were selected for progenitor cells before initiation of cultures. This indicates that at least in part cells contribute to this observation are removed during the selection process. We focused on T cells as potent producers of cytokines and could show that the physical elimination or functional abrogation of T cells leads to a dramatic decrease in cell number proliferation, percentage of living cells, and overall number of hematopoietic progenitor cells (Table 4) .
The most attractive explanation for this observation is that T cells produce stimulating (soluble) factors which our cytokine combination without serum or serum substitutes was lacking. These factors seem to be mandatory to keep mononuclear cells alive in static cultures and allow hematopoietic progenitor cell growth and differentiation.
During culture cord blood cells are driven through multiple cell divisions by cytokine stimulation. We investigated the genetic integrity of these expanded cells using conventional cytogenetic analyses, since the safe clinical use of in vitro manipulated cells requires a genetically intact graft. All metaphases of the cord blood MNCs examined on day 0 revealed normal karyotypes. Sporadic chromosomal aberrations were found in 4% of the metaphases of samples examined after 7-20 days of ex vivo expansion including one numerical and three structural chromosome changes. This falls within the frequencies of 0.5-5% of sporadic chromosome abnormalities in short-term (1-3 days) bone marrow cultures of normal individuals. 30, 31 Moreover, the chromosome abnormalities were observed in one cord blood (CB013) sample, only. A mutagenic exposure of the fetus during gestation and/or an inherited chromosome instability syndrome may have contributed to the increased fragility in this sample. However, our data demonstrate that sporadic chromosome abnormalities are found in prolonged cytokine stimulated cord blood MNC cultures.
